BRIEF: Hutchmed profit falls on shrinking R&D income

0013.HK HCM.US

Hutchmed (China) Ltd. (HCM.US; 0013.HK; HCM.L), a biopharmaceutical company controlled by CK Hutchison Holdings (0001.HK), said its revenue fell 24.8% last year to $630 million, according to its annual results published on Wednesday. The company also reported a second consecutive year of profitability, though last year’s profit of $37.73 million was down 62.6% from 2023.

The company said that, including overseas sales in collaboration with Japan’s Takeda Pharmaceuticals, its total oncology product sales grew by 134% last year to $501 million. The company’s overall revenue decline mainly owed to a decrease in R&D income from its partners. Notably, upfront payments, regulatory milestone payments and R&D service revenue from Takeda dropped from $345.9 million in 2023 to $67 million last year.

Meanwhile, Hutchmed and Innovent Biologics (1801.HK) jointly announced that the FRUSICA-2 China Phase II/III study for the treatment of advanced renal cell carcinoma met its primary endpoint. Hutchmed’s stock opened up 3.7% on Thursday in Hong Kong, and closed up 9.41% at HK$26.15 at the midday break.

By Lee Shih Ta

To subscribe to Bamboo Works weekly free newsletter, click here

,
, , ,

Related Articles

RELATED ARTICLES

  1. NEWS WRAP: Hutchmed sells non-core asset to focus on cancer treatment
    0013.HK HCM.US
  2. Inmagene Bio charts backdoor to U.S. listing with offshore acquisition
    IKNA.US
  3. Growing profits, shrinking market share test ZTO’s strategy
    2507.HK ZTO.US
  4. BRIEF: Huya’s revenue, profit fall as user base keeps shrinking
    HUYA.US
  5. BRIEF: Ascentage Pharma gets Chinese regulatory nod for U.S. listing
    6855.HK
  6. BRIEF: Giordano’s profit falls 30% in 2024
    0709.HK
  7. BRIEF: SMIC’s fourth-quarter revenue jumps, but profit falls
    0981.HK 688981.SHG
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

Recent Articles

Illustration of the rebound of Chinese fintech lenders

A fintech lender rebound, and a hotel mess

Fintech lenders are entering a new golden era, with Jiayin reporting 46% growth for its core consumer lending business in last year's fourth quarter and forecasting similar gains this year. What's driving this rebound? And hotelier H World is still trying to fix a German acquisition from 2019 that wiped out its profit in the fourth quarter of last year. Will the Chinese hotelier be able to turn around this money-losing offshore asset?
JFIN.US HTHT.US